# Roche to acquire GenMark Diagnostics for $1.8 billion

Roche signed a definitive merger agreement to acquire GenMark Diagnostics for $24.05 per share, totaling approximately $1.8 billion. GenMark's molecular diagnostic tests complement Roche's portfolio.

- Type: Acquisition
- Announced: 2021-03-15
- Where: Carlsbad, California, United States
- Value: $1.80B
- Status: announced
- Products: molecular diagnostic tests, ePlex platform
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Roche Holdings Inc](https://endata.com/companies/16415.md) (acquirer)
- [GenMark Diagnostics](https://endata.com/companies/53822.md) (target)

## Sources

- [roche.com](https://www.roche.com/media/releases/med-cor-2021-03-15b), 2021-03-15: "The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs."
- [roche.com](https://www.roche.com/investors/updates/inv-update-2021-03-15), 2021-03-15: "The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.